GKL-006Allo Injection in Patients With Advanced Solid Tumors
ConditionSolid Tumor Malignancies
Trial statusNot yet recruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-75
SponsorBeijing Gene Key Life Technology Co., Ltd
About this trial
This is a Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary anti-tumor activity of GKL-006Allo Injection in participants with advanced solid tumors.
Eligibility criteria
Qualifiers
Able to understand and voluntarily sign the informed consent form.
Aged 18 to 75 years.
Histologically, cytologically or clinical confirmed unresectable locally advanced or metastatic solid tumor that has failed standard therapy.
At least one measurable tumor lesion during screening according to RECIST v1.1.
Disqualifiers
Recently received radical radiotherapy or other anti-tumor therapy.
Known hypersensitivity to any component of the study treatment.
Prior history or concurrent malignancy that has not been cured.
Active infection, known or suspected autoimmune disease.
Trial design
Treatments tested in this trial
- GKL-006Allo Injection
Treatment groups
27 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov